Paper11323675
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
Shankaran V and 6 others. Nature, 2001. Cited by 2,111 papers, by iCite.
Cite this record
ConductScience Library. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Papers, record 11323675. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11323675
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma | Major topic |
| Interferon-gamma | Major topic |
| Lymphocytes | Major topic |
| Sarcoma, Experimental | Major topic |
| ATP Binding Cassette Transporter, Subfamily B, Member 2 | |
| ATP-Binding Cassette Transporters | |
| Animals | |
| DNA-Binding Proteins | |
| Female | |
| H-2 Antigens | |
| Immunocompetence | |
| Immunophenotyping | |
| Methylcholanthrene | |
| Mice | |
| Neoplasm Transplantation | |
| Retroviridae |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02259621 | Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC | Background |
Source ClinicalTrials.gov
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9636188 | Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. | Proc Natl Acad Sci U S A | 1998 | https://conductscience.org/library/papers/9636188 | PubMed |
| 2 | 8608598 | Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. | Cell | 1996 | https://conductscience.org/library/papers/8608598 | PubMed |
| 3 | 202188 | Immunogenetics of cell surface antigens of mouse leukemia. | Annu Rev Genet | 1977 | https://conductscience.org/library/papers/202188 | PubMed |
| 4 | 7895156 | Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. | Immunity | 1994 | https://conductscience.org/library/papers/7895156 | PubMed |
| 5 | 283266 | Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. | J Natl Cancer Inst | 1979 | https://conductscience.org/library/papers/283266 | PubMed |
| 6 | 10802618 | TAP expression provides a general method for improving the recognition of malignant cells in vivo. | Nat Biotechnol | 2000 | https://conductscience.org/library/papers/10802618 | PubMed |
| 7 | 4588620 | Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. | Science | 1974 | https://conductscience.org/library/papers/4588620 | PubMed |
| 8 | 9164943 | Allelic variation in the mouse Tap-1 and Tap-2 transporter genes. | J Immunol | 1997 | https://conductscience.org/library/papers/9164943 | PubMed |
| 9 | 8608597 | Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. | Cell | 1996 | https://conductscience.org/library/papers/8608597 | PubMed |
| 10 | 10605607 | Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. | Adv Immunol | 2000 | https://conductscience.org/library/papers/10605607 | PubMed |
| 11 | 8456301 | Immune response in mice that lack the interferon-gamma receptor. | Science | 1993 | https://conductscience.org/library/papers/8456301 | PubMed |
| 12 | 25291286 | T-cell function and specificity in athymic mice. | Immunol Today | 1983 | https://conductscience.org/library/papers/25291286 | PubMed |
| 13 | 4921480 | The concept of immunological surveillance. | Prog Exp Tumor Res | 1970 | https://conductscience.org/library/papers/4921480 | PubMed |
| 14 | 7584155 | Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. | Immunity | 1995 | https://conductscience.org/library/papers/7584155 | PubMed |
| 15 | 2953792 | The composition of the T cell receptor repertoire in nude mice. | J Immunol | 1987 | https://conductscience.org/library/papers/2953792 | PubMed |
| 16 | 10684858 | Differential tumor surveillance by natural killer (NK) and NKT cells. | J Exp Med | 2000 | https://conductscience.org/library/papers/10684858 | PubMed |
| 17 | 1547487 | RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. | Cell | 1992 | https://conductscience.org/library/papers/1547487 | PubMed |
| 18 | 10974040 | Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. | J Exp Med | 2000 | https://conductscience.org/library/papers/10974040 | PubMed |
| 19 | 446837 | Spontaneous tumors in nude mice: effect of the viable yellow gene. | Exp Cell Biol | 1979 | https://conductscience.org/library/papers/446837 | PubMed |
| 20 | 8920866 | Decreased tumor surveillance in perforin-deficient mice. | J Exp Med | 1996 | https://conductscience.org/library/papers/8920866 | PubMed |
Cited by1,223
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,111 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953139 | Reconciling CD8 T cell subsets: GZMK+, cytotoxic, resident memory, exhausted, and other CD8 T cells in blood and tissue. | Front Immunol | 2026 | https://conductscience.org/library/papers/42953139 | PubMed |
| 42908192 | Oncolytic Virus-Engineered Extracellular Vesicles Rewire Glioblastoma Immunity. | J Extracell Vesicles | 2026 | https://conductscience.org/library/papers/42908192 | PubMed |
| 42856641 | Epithelial to mesenchymal transition and M2 macrophages drive aggressiveness in murine and human sarcomatoid urothelial carcinoma. | bioRxiv | 2026 | https://conductscience.org/library/papers/42856641 | PubMed |
| 42826198 | An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy. | Sci Adv | 2026 | https://conductscience.org/library/papers/42826198 | PubMed |
| 42763389 | Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42763389 | PubMed |
| 42738409 | The Immune Landscape of Chondrosarcoma: A Review of Tumor-Related Immune Cells. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738409 | PubMed |
| 42735303 | Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/42735303 | PubMed |
| 42716945 | Peritoneal ovarian cancer growth in the omentum proceeds independently of mature adipocytes. | Nat Commun | 2026 | https://conductscience.org/library/papers/42716945 | PubMed |
| 42666925 | Cryoablation combined with immunotherapy: new strategies and progress in the treatment of tumors. | Front Oncol | 2026 | https://conductscience.org/library/papers/42666925 | PubMed |
| 42649983 | 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649983 | PubMed |
| 42588715 | Trans-Presentation of IL-15 by IL15Rα Attenuates Tumor Immune Surveillance and Is Dispensable for IL-15-Dependent Tumor Growth Control. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588715 | PubMed |
| 42469575 | 5-FU chemotherapy induces functional CD7+ and IL7R+ CTLs infiltration to suppress colorectal tumor progression. | Sci China Life Sci | 2026 | https://conductscience.org/library/papers/42469575 | PubMed |
| 42437767 | Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42437767 | PubMed |
| 42412123 | SHIP1 is required for T cell surveillance of occult malignancies. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/42412123 | PubMed |
| 42396206 | pVACtools v6: A comprehensive suite for neoantigen prediction, visualization, and therapy design. | ArXiv | 2026 | https://conductscience.org/library/papers/42396206 | PubMed |
| 42347594 | Therapeutic Cancer Vaccines in B-Cell Malignancies and Multiple Myeloma. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42347594 | PubMed |
| 42327767 | The intratumoral microbiome: a review of the tumor microenvironment's fourth axis shaping anti-tumor immunity, cancer prognosis, and therapeutic response. | Front Immunol | 2026 | https://conductscience.org/library/papers/42327767 | PubMed |
| 42297823 | Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/42297823 | PubMed |
| 42276071 | Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors. | Immunity | 2026 | https://conductscience.org/library/papers/42276071 | PubMed |
| 42168613 | Beyond sex determination: the Y chromosome in male cancers. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/42168613 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| RAG2 | 5897 | PubTator's text mining | https://conductscience.org/library/genes/5897 | NCBI Gene |
| TAP1 | 6890 | PubTator's text mining | https://conductscience.org/library/genes/6890 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11323675
GET https://conductscience.org/api/papers/v1/11323675/cited_by?page=2